Other languages Sol-Gel Technologies Ltd.

Equities

SLGL

IL0011417206

Market Closed - Nasdaq Other stock markets 02:00:01 02/05/2024 am IST			5-day change	1st Jan Change
0.782 ^USD	+9.75%		-15.00%	-29.23%

13/03	Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
29/02	Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Sol-Gel Technologies Ltd. Elects Yuval Yanai as External Director	29/02
Sol-Gel Technologies Ltd. Screens First Patient for SGT-610 Phase 3 Study	30/11
Sol-Gel Technologies Ltd. Announces Resignation of Shmuel Ben Zvi from Board	20/11
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10
Sol-Gel Technologies Ltd. Appoints Sharon Kochan to the Board of Directors	28/23/28
Sol-Gel Technologies, Searchlight Pharma Sign Licensing Deals for 2 Dermatology Drugs	06/23/06
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO and EPSOLAY in Canada	06/23/06
Sol-Gel Technologies Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10
Sol-Gel Technologies Launches $22.8 Million Registered Direct, Private Placement Offerings; Shares Drop Pre-Bell	27/23/27
Sol-Gel Technologies Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22/22/22
Sol-Gel Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/22/04
Sol-Gel Technologies Secures FDA Approval for EPSOLAY	25/22/25
Sol-Gel Technologies Announces FDA Approval of EPSOLAY	25/22/25
Sol-Gel Grants Galderma Holding SA the Exclusive Rights to Commercialize EPSOLAY in the United States	25/22/25
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO	14/22/14
Sol-Gel Technologies Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sol-Gel Technologies Ltd.

Equities

SLGL

IL0011417206

Other languages

Filters